ImmunoGen earns $4M milestone from Sanofi
Massachusetts, USA-based biopharmaceutical firm ImmunoGen, which develops targeted anticancer therapeutics, says it has earned a $4.0-million milestone payment from French drug major Sanofi-Aventis with the initiation of a Phase II clinical trial with AVE1642.
"Sanofi-Aventis is making solid progress with AVE1642 and is committed to evaluating this compound for a number of types of cancers," commented Daniel Junius, chief operating officer of the US firm. "While ImmunoGen is principally known for our Tumor-Activated Prodrug technology, we have well-established antibody development capabilities, as reflected in AVE1642," he added.
AVE1642 was developed by ImmunoGen using the firm's expertise in monoclonal antibodies and cancer biology, and was humanized using its proprietary resurfacing technology. The agent was licensed to Sanofi-Aventis as part of a broader collaboration between the companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze